New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AAPL;JPM;RDSA;NVS;BKS;WDC;GD;VIA;VIAB;BLK;MPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
April 21, 2015
08:20 EDTAAPLOrbitz app now customized for Apple Watch
Subscribe for More Information
06:31 EDTJPMJPMorgan names Chien, Li as co-heads of Greater China banking, WSJ reports
Subscribe for More Information
06:18 EDTAAPLCitigroup unenthused with IBM mix, still prefers Apple
Subscribe for More Information
05:58 EDTAAPLReport: AU Optronics to supply Apple with iPhone panels, DigiTimes says
Subscribe for More Information
05:26 EDTNVSNovartis says data shows Gilenya high efficacy
Novartis announced new analysis from the Phase III FREEDOMS and FREEDOMS II. The data showed that previously-treated patients with highly-active relapsing multiple sclerosis, or RMS, who were treated with Gilenya had a six-times greater likelihood of achieving 'no evidence of disease activity' across four key measures of disease activity compared to placebo over two years. This is referred to as NEDA4 and is achieved when a patient with RMS has no relapses, no new MRI lesions, no MS-related brain shrinkage and no disability progression. This analysis was the first time patients with highly-active RMS who had been treated in the previous year with an injectable therapy were assessed using the NEDA4 definition that includes brain shrinkage. Brain shrinkage is a marker of the widespread inflammatory damage in the central nervous system and is associated with accumulated loss of function. By using this updated NEDA4 definition, physicians are able to get a more complete picture of a patient's disease and response to treatment, which is crucial to identify the optimal therapy to slow short- and long-term disease progression. This is especially important for people with highly-active RMS, who are at a greater risk of relapses and future loss of function, and may therefore require a different treatment approach.
April 20, 2015
19:32 EDTJPMU.S. pressures JPMorgan, Citi, others to settle forex case by mid-May, FT says
The U.S. Department of Justice is pressuring JPMorgan (JPM), Barclays (BCS), Citi (C), Royal Bank of Scotland (RBS), and UBS (UBS) to reach a settlement by mid-May regarding alleged foreign exchange manipulation, reports the Financial Times, citing people familiar with the situation. The Financial Times notes that the settlement could see some of the banks paying roughly $1B. Sources say that the Department is demanding guilty pleas from "most" of the banks. Reference Link
16:01 EDTAAPLOptions Update; April 20, 2015
iPath S&P 500 VIX Short-Term Futures down 78c to 21.52. Option volume leaders: AAPL VZ PBR TWTR TSLA TWTR NFLX MCP FB AMZN AA C according to Track Data.
15:35 EDTMPCSenator to introduce legislation to repeal U.S. crude export ban, Fuelfix says
Senator Lisa Murkowski, the head of the Senate Energy and Natural Resources Committee, pledged during the IHS Energy CERAWeek conference to advance legislation lifting the U.S. ban on crude oil exports, reported Fuelfix. Publicly traded refiners include Delek US (DK), HollyFrontier (HFC), Marathon Petroleum (MPC), Phillips 66 (PSX), Tesoro (TSO), Valero (VLO) and Western Refining (WNR). Reference Link
14:56 EDTMPCSenator to introduce legislation to repeal U.S. crude export ban, Reuter says
Subscribe for More Information
13:24 EDTBLKSEC charges BlackRock Advisors with breaching fiduciary duty
Subscribe for More Information
12:31 EDTNVSOn The Fly: Top stock stories at midday
Stocks on Wall Street were higher at midday after China’s central bank relaxed reserve requirements for its banks. The nation's own stock market struggled to overcome the cross current of other actions taken to cut down on speculative trading there, but U.S. stock markets surged at the open and had not looked back by midday. The domestic economic calendar has quiet and earnings continue to be the focal point at home, as a great number of S&P 500 companies prepare to report this week. ECONOMIC EVENTS: In the U.S., the Chicago Fed National Activity Index had a reading of -0.42, versus expectations for a +0.10 reading. A reading below zero represents economic activity below trend. In China, the People's Bank of China cut the reserve-requirement ratio, or the amount of reserves lenders need to hold, by 1 full percentage point, which was the biggest cut since the depths of the financial crisis and more than expected by economists. However, the Shanghai Composite Index still dropped 1.6%, since the reserve-requirement cut came after regulators had moved to curb speculative trading with actions taken Friday. COMPANY NEWS: Shares of Morgan Stanley (MS) advanced 1% after the bank's headline earnings excluding certain adjustments and tax benefits beat expectations. CEO James Gorman noted that the first quarter of the year was the bank's "strongest quarter in many years with improved performance across most areas of the firm." Morgan Stanley also increased its quarterly dividend to 15c per share from 10c per share. MAJOR MOVERS: Among the notable gainers was Hasbro (HAS), which gained 10% after the toymaker's sales and profits widely topped expectations in its fiscal first quarter. Also higher was Rovi (ROVI), which gained more than 10% after the company announced it has renewed its patent license and interactive program guide product agreement with Charter Communications (CHTR). Among the noteworthy losers was FARO Technologies (FARO), which dropped 25% and was downgraded by Noble Financial and Needham after the preannounced lower than expected first quarter revenue. Also lower were a number of companies that are developing CAR-T cancer therapies following the annual meeting of the American Association for Cancer Research. Mizuho analyst Peter Lawson attributed the pullback to disappointment in this weekend's solid tumor data on a small number of patients with advanced cancers who were given CAR-T therapy developed by Novartis (NVS) and the University of Pennsylvania. Shares of Kite Pharma (KITE), Juno Therapeutics (JUNO), blue bird bio (BLUE), and ZIOPHARM Oncology (ZIOP) were all lower near noon. INDEXES: Near midday, the Dow was up 236.19, or 1.32%, to 18,062.49, the Nasdaq was up 59.54, or 1.21%, to 4,991.35, and the S&P 500 was up 21.82, or 1.05%, to 2,103.00.
11:44 EDTNVSCAR-T therapy stocks fall following cancer research meeting
Subscribe for More Information
09:36 EDTAAPLActive equity options trading on open
Subscribe for More Information
09:20 EDTNVSLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
08:42 EDTAAPLApple May weekly volatility elevated into Q2 and outlook
Subscribe for More Information
08:18 EDTAAPLApple Q2 EPS estimate raised above consensus at Pacific Crest
Pacific Crest raised its Q2 EPS estimate for Apple to $2.17 from $2.15, putting it above the consensus estimate of $2.14. The firm raised its Q2 estimate based on an increase in its iPhone unit outlook, and raised its fiscal 2015 and fiscal 2016 EPS estimates for the company based on higher iPhone and Apple Watch estimates. Nonetheless the firm expects the company to face growth challenges in fiscal 2016, and it keeps a Sector Weight rating on the shares.
07:30 EDTAAPLApple Q2 results likely to beat expectations, says Wells Fargo
Subscribe for More Information
07:20 EDTNVSAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:18 EDTNVSAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
06:19 EDTMPCCiti still bullish on U.S. Refiners, Marathon Petroleum a top pick
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use